ApoA1 is a major protein component of high density lipoproteins (HDL)
which is associated with reversed cholesterol transport, lipid/cholesterol
binding, lecithin/cholesterol acyltransferase (LCAT) activation and specific
receptors binding. It is synthesized in the liver and small intestine.
Defects of ApoA1 cause low HDL level and systemic non-neuropathic
amyloidosis. Serum concentration of ApoA1 is inversely related to the risk
of developing atherosclerosis.
